Jacob Plieth Edwin Elmhirst It took nearly two decades from the start of tremelimumab’s first-in-human study until Astrazeneca saw the drug approved last week as Imjudo. This is undoubtedly a lesson in perseverance, but it does not in fact represent the longest development period of a drug from phase 1 to US approval. That honour,...
